Skip to main content

Table 2 Characteristics of eligible trials for general sarcoma with biologically based treatment for phase I and phase II

From: Comprehensive analysis of published phase I/II clinical trials between 1990-2010 in osteosarcoma and Ewing sarcoma confirms limited outcomes and need for translational investment

Author Year Intervention No Osteo Patients No Ewing Patients Phase Outcome
Daw et al, J Clin Oncol, 23 (25): 6172-80 [40] 2005 Gefitinib 6 3 I 1 (4%) PR, 4 (16%) SD
Maki et al, Cancer, 103 (7): 1431-8 [41] 2005 Bortezomib 1 2 II 1 (4%) OR
Villablanca et al, J Clin Oncol, 24 (21): 3423-30 [42] 2006 Fenretinide 2 5 I 1 (2%) CR, 13 (24%) SD
Biron et al, ASCO abstract 2007 Gimatecan 0 Not mentioned II 3 (8%) SD
Bagatell et al, Clin Cancer Res, 13 (6): 1783-8 [43] 2007 Tanespimycin 6 2 I 0% OR
Jimeno et al, Pediatr Blood Cancer, 49 (3): 352-7 [44] 2007 Gefitinib 3 1 I 1 (7%) PR, 3 (20%) SD
Kramer et al, J Clin Oncol, 25 (34): 5465-70 [45] 2007 Monoclonal antibody(131-I-3F8) 0 2 I 3 (23%) ClR
Bond et al, Pediatr Blood Cancer, 50 (2): 254-8 [46] 2008 Imatinib mesylate 10 24 II 1 (1%) PR
Chao et al, ASCO abstract 2008 Imatinib mesylate 0 7 II 1 (14%) PR
Fox et al, Clin Cancer Res, 14 (4): 1111-5 [47] 2008 Tubulin Inhibitor (ABT-751) 3 3 I 0% OR
Jakacki et al, J Clin Oncol, 26 (30): 4921-7 [48] 2008 Erlotinib, Temozolomide 1 0 I 1 (2%) SD
Langevin et al, Pediatr Blood Cancer, 50 (3): 577-80 [49] 2008 Rebeccamycin 16 14 II % OR
Mita et al, J Clin Oncol, 26 (3): 361-7 [50] 2008 Deforolimus 1 1 I 4 (13%) PR, 18 (56%) SD
Olmos et al, ASCO abstract 2008 Figitumumab 0 9 I 1 (5%) PR, 6 (27%) SD
Chawla et al, Mol Ther, 17 (9): 1651-7 [51] 2009 Rexin-G 3 1 I/II 13 (65%) SD
Chugh et al, J Clin Oncol, 27 (19): 3148-53 [52] 2009 Imatinib 27 13 II 1 (0.5%) CR, 3 (2%) PR
Malempati et al, ASCO abstract 2009 Cixutumumab Not mentioned 10 I 1 (4%) PR
Patel et al, ASCO abstract 2009 IGF-1R antibody (R1507) 43 71 II Not mentioned
Widemann et al, J Clin Oncol, 27 (4): 550-6 [53] 2009 Ixabepilone 3 2 I 4 (21%) SD
Jacobs et al, Clin Cancer Res, 16 (2): 750-4 [54] 2010 Ixabepilone 11 9 II 0% OR
Kurzrock et al, Clin Cancer Res, 16 (8): 2458-65 [55] 2010 IGF-1R antibody (R1507) 0 9 I 2 (5%) PR, 13 (35%) SD
Olmos et al, Lancet Oncol, 11: 129-35 [56] 2010 Figitumumab 0 16 I 1 (3%) CR, 1 (3%) PR, 8 (28%) SD
  1. Abbreviations:, ClR = Clinical Response; CR = Complete Response; Cyclo = cyclophosphamide; Doxo = doxorubicin; EFS = Event Free Survival; Etop = etoposide; Ewing = Ewing Sarcoma; Ifos = ifosfamide; No = number; OR = Objective Response; Osteo = Osteosarcoma; PR = Partial Response; RR = Response Rate; SCR = Stem Cell Rescue; SD = Stabile Disease; TMR = Total Marrow Radiation; Vin = vincristine